Interim analysis of the AVETUXIRI Trial: Avelumab combined with cetuximab and irinotecan for treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC)—A proof of concept, open-label, nonrandomized phase IIa study.

Marc Van den Eynde,Nicolas Huyghe,Astrid De Cuyper,Isabelle Sinapi,Marie Ferrier,Mélanie Gilet,Aline Van Maanen,Marie-Laure Castella,Jérôme Galon,Javier Carrasco

Interim analysis of the AVETUXIRI Trial: Avelumab combined with cetuximab and irinotecan for treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC)—A proof of concept, open-label, nonrandomized phase IIa study.

2021

Marc Van den Eynde
Nicolas Huyghe
Astrid De Cuyper
Isabelle Sinapi
Marie Ferrier
Mélanie Gilet
Aline Van Maanen
Marie-Laure Castella
Jérôme Galon
Javier Carrasco

80Background: Immune checkpoint inhibitors have demonstrated poor efficacy in MSS mCRC. Previous research indicate that cetuximab (anti-EGFR chimeric monoclonal antibody) could initiate, independen...

Keywords:

Medicine
Internal medicine
Interim analysis
Avelumab
Oncology
Microsatellite Stable
Irinotecan
Monoclonal antibody
Colorectal cancer
Refractory
Cetuximab

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations